About Aura Biosciences, Inc.
https://www.aurabiosciences.comAura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
CEO
Elisabet de los Pinos
Compensation Summary
(Year 2021)
ETFs Holding This Stock
Summary
Showing Top 3 of 75
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
MATRIX CAPITAL MANAGEMENT COMPANY, LP
Shares:6.92M
Value:$36.41M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:5.1M
Value:$26.83M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:4.88M
Value:$25.67M
Summary
Showing Top 3 of 113
About Aura Biosciences, Inc.
https://www.aurabiosciences.comAura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $27.61M ▼ | $-26.13M ▲ | 0% | $-0.4 ▲ | $-25.8M ▲ |
| Q2-2025 | $0 | $28.31M ▼ | $-27.02M ▲ | 0% | $-0.47 ▲ | $-26.67M ▲ |
| Q1-2025 | $0 | $29.04M ▲ | $-27.48M ▼ | 0% | $-0.55 ▼ | $-28.74M ▼ |
| Q4-2024 | $0 | $27.52M ▲ | $-25.83M ▼ | 0% | $-0.52 ▼ | $-25.52M ▼ |
| Q3-2024 | $0 | $23.23M | $-21.04M | 0% | $-0.42 | $-22.92M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $161.87M ▼ | $190.02M ▼ | $33.36M ▲ | $156.67M ▼ |
| Q2-2025 | $177.31M ▲ | $204.4M ▲ | $29.77M ▲ | $174.63M ▲ |
| Q1-2025 | $127.99M ▼ | $155.4M ▼ | $27.43M ▼ | $127.97M ▼ |
| Q4-2024 | $151.09M ▼ | $182.5M ▼ | $30.53M ▼ | $151.97M ▼ |
| Q3-2024 | $174.38M | $205.34M | $30.67M | $174.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-26.13M ▲ | $-20.14M ▲ | $-44.02M ▼ | $4.36M ▼ | $-59.81M ▼ | $-20.19M ▲ |
| Q2-2025 | $-27.02M ▲ | $-20.77M ▲ | $19.98M ▼ | $69.93M ▲ | $69.14M ▲ | $-20.81M ▲ |
| Q1-2025 | $-27.48M ▼ | $-23.36M ▲ | $29.81M ▲ | $96K ▼ | $6.53M ▲ | $-23.54M ▲ |
| Q4-2024 | $-25.83M ▼ | $-23.95M ▼ | $29.7M ▲ | $543K ▼ | $6.29M ▲ | $-24.25M ▼ |
| Q3-2024 | $-21.04M | $-15.27M | $9.89M | $716K | $-4.67M | $-15.61M |
CEO
Elisabet de los Pinos
Compensation Summary
(Year 2021)
ETFs Holding This Stock
Summary
Showing Top 3 of 75
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
MATRIX CAPITAL MANAGEMENT COMPANY, LP
Shares:6.92M
Value:$36.41M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:5.1M
Value:$26.83M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:4.88M
Value:$25.67M
Summary
Showing Top 3 of 113